Cibus, Inc. (NASDAQ:CBUS) CFO Sells $24,629.10 in Stock

Cibus, Inc. (NASDAQ:CBUS) CFO Carlo Broos sold 4,647 shares of the stock in a transaction dated Tuesday, November 12th. The shares were sold at an average price of $5.30, for a total value of $24,629.10. Following the completion of the sale, the chief financial officer now directly owns 74,197 shares in the company, valued at $393,244.10. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Cibus Price Performance

NASDAQ CBUS opened at $4.90 on Thursday. The firm’s fifty day moving average price is $4.05 and its 200 day moving average price is $8.60. Cibus, Inc. has a 12 month low of $2.86 and a 12 month high of $23.18. The company has a market capitalization of $129.63 million, a price-to-earnings ratio of -0.22 and a beta of 1.79.

Institutional Trading of Cibus

Institutional investors and hedge funds have recently made changes to their positions in the company. SG Americas Securities LLC acquired a new position in Cibus during the third quarter worth approximately $33,000. Swan Global Investments LLC acquired a new stake in Cibus during the 3rd quarter worth $115,000. Charles Schwab Investment Management Inc. grew its position in Cibus by 14.6% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 49,285 shares of the company’s stock worth $161,000 after purchasing an additional 6,276 shares during the last quarter. FineMark National Bank & Trust increased its stake in Cibus by 24.3% in the second quarter. FineMark National Bank & Trust now owns 20,488 shares of the company’s stock valued at $202,000 after purchasing an additional 4,000 shares during the period. Finally, Squarepoint Ops LLC acquired a new stake in shares of Cibus during the second quarter worth about $214,000. 33.81% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on CBUS. Alliance Global Partners cut their target price on shares of Cibus from $25.00 to $23.50 and set a “buy” rating on the stock in a research note on Tuesday, September 24th. Canaccord Genuity Group reissued a “buy” rating and issued a $20.00 price objective on shares of Cibus in a research report on Tuesday, October 22nd. HC Wainwright reaffirmed a “buy” rating and set a $25.00 price objective on shares of Cibus in a research report on Monday. Finally, Canaccord Genuity Group upgraded shares of Cibus to a “strong-buy” rating in a research note on Friday, July 19th.

Cibus Company Profile

Cibus, Inc, a agricultural biotechnology company, develops and licenses plant traits to seed companies for royalties. The company primarily focus on trait productivity in two areas, including productivity traits that enable farmers to have higher yields and reduce the use of the crop protection chemicals and fertilizers; and sustainable ingredients that enable corporations to replace ingredients that are fossil fuel based or whose production results in increased greenhouse gases.